Riitta Lassila on LMWH Benefits in COVID19
Riitta Lassila, Professor of Coagulation Medicine at University of Helsinki, shared on LinkedIn:
”We are happy to report RDW benefits from early high risk (the same for corona disease progression and thrombosis) – targeted LMWH prophylaxis initiated at outpatient setting.
The two first virus waves when vaccination program had only started.
Lessons for any future severe viral outbursts.”
Read the full article here.
Article: Early outpatient use of low-molecular-weight heparin benefits COVID-19 outcome in association with hospitalization – Lessons learned
Authors: Miika Koskinen, Eeva Ruotsalainen, Mia Wallin, Hilkka Kivelä, Kerstin Carlsson, Jari Petäjä, Eero Hirvensalo, Markku Mäkijärvi, Riitta Lassila
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 29, 2026, 15:50Sweta Agrawal: Expanding Care for PNH Patients in Nepal
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice
-
Jun 29, 2026, 14:30Bruno Pougault: Pregnancy and Thrombosis – Balancing Evolutionary Protection Against Clinical Risk
-
Jun 29, 2026, 13:32Omid Seidizadeh: The Full VWD Session from EHA 2026 Is Now Available to Watch
-
Jun 29, 2026, 13:22Cheryl Carcel: Make The Stroke Research More Inclusive for Women, Take The Survey
-
Jun 29, 2026, 13:18Bianca Rocca: New Expert Opinion On the Evolving Debate on Factor XI as a Therapeutic Target
-
Jun 29, 2026, 13:06Francisco Chacón-Lozsán: Intermittent Hemodialysis in the ICU Should not be Monitored Only by ‘Session Completed’